Extended Data Fig. 12: LXR unlinks intestinal regeneration and tumorigenesis.

Schematics showing the proposed model. Left side: intestinal tissue damage leads to increased expression of the enzyme Cyp27a1, which metabolizes oxysterol ligands for LXR. Either endogenous or synthetic (GW3965) LXR ligands act in epithelial cells to induce the EGFR ligand amphiregulin (Areg) promoting intestinal epithelial regeneration. Right side: In the context of tumour development, LXR activation amplifies anti-tumour immunity (dependent on B cells and CD8 T cells) controlling intestinal tumour growth.